The increase in patient awareness and the longer life expectancies are driving the growth of the Chinese diabetes market. There is potentially great opportunity for multinational pharmaceutical companies seeking to penetrate the antidiabetic therapies market in China. However, many drugs that are launched in the West, such as SGLT-2 inhibitors and long-acting release GLP-1 analogues, are not yet available in China, and the most recently launched DPP-IV inhibitors and short-acting GLP-1 analogues are still optimizing uptake in this highly lucrative market. Navigating the road to reimbursement and optimizing market access are, therefore, challenging.
Questions Answered in This Report:
- What are Chinese physicians’ antidiabetic drugs of choice across different lines of therapy?
- Do the safety concerns about rosiglitazone and pioglitazone affect the prescribing pattern of PPAR-gamma agonists? What are the replacements for PPAR-gamma agonists among physicians who no longer prescribe them?
- What are the typical prescribing patterns of DPP-IV inhibitors and GLP-1 analogues in the current treatment algorithms? What is the current brand share within each drug class? How will these patterns change by 2017 after entry of new therapies?
- What is the discontinuation rate for DPP-IV inhibitors and GLP-1 analogues, and what are the main reasons for cessation of such therapy?
- What clinical and reimbursement barriers do physicians face in prescribing DPP-IV inhibitors and GLP-1 analogues?
- Which agents are currently included on the National Reimbursement Drug List (NRDL) and/or Provincial Reimbursement Drug Lists (PRDLs), and what reimbursement restrictions apply? What therapies do payers expect to be included in the new versions of the NRDL and/or PRDLs? How might reimbursement of currently approved antidiabetic therapies change in the near future?
- What are payers’ views on the pricing and reimbursement landscape for current and emerging antidiabetic therapies? What challenges will manufacturers face in the domestic market?
- How will market access barriers evolve, and what challenges are companies likely to face in the future in China?
- How do payers and prescribers perceive emerging DPP-IV inhibitors and GLP-1 analogues? How do payers and prescribers perceive the new SGLT-2 inhibitors?
- How will current prescribing practices be affected by the launch of emerging agents and generic versions of DPP-IV inhibitors and GLP-1 analogues?
This Emerging Markets Physician & Payer Forum report explores the market access opportunities and obstacles that will impact the treatment of type 2 diabetes in China in the next two to three years.
Markets covered: China.
Primary research: This report draws on insights from surveyed 50 physicians (31 endocrinologists/ diabetologists and 19 primary care physicians), as well as interviews with payers who influence pricing and reimbursement decisions.. Payers come from the following backgrounds: Advisor, Ministry of Human Resources and Social Security (MOHRSS), Beijing; Advisor, Endocrine Medical Association, Qiqihar; Advisor, China Food and Drug Administration (CFDA), Beijing.
Epidemiology: Prevalence of diabetes.
Emerging therapies: Phase III: 5 drugs; preregistration: 2 drugs.